Arecor Therapeutics, a leading biotech company based in Cambridge, has announced a significant new partnership with a major global pharmaceutical firm to develop an enhanced formulation of one of the partner’s proprietary products.
Revealed on Wednesday, the agreement marks another major milestone for the AIM-listed company, which continues to gain international recognition for its formulation expertise. Arecor will use its proprietary Arestat™ technology platform to improve the drug’s characteristics, potentially increasing stability, efficacy, or patient usability.
While the name of the pharmaceutical partner remains confidential, the nature of the agreement—a formulation study—opens the door to future licensing deals depending on development outcomes.
Dr Sarah Howell, Chief Executive Officer of Arecor, described the deal as further validation of the company’s position at the forefront of drug delivery innovation.
Arecor continues to partner with the world’s leading pharmaceutical companies, which is testament to our leadership position in the field of drug delivery and formulation innovation,” Howell said. “This agreement demonstrates the potential of our Arestat platform to create enhanced formulations that would otherwise be unachievable.
Headquartered in the heart of one of the UK’s most innovative life sciences hubs, Arecor has steadily built a reputation for turning difficult-to-formulate drugs into viable, patient-friendly therapies. The Arestat platform enables the company to reformulate medicines in ways that can improve dosing, shelf life, and convenience, benefitting both patients and healthcare systems.
This latest announcement highlights the strength of Cambridge’s biotech sector, which continues to punch above its weight on the global stage. As pharmaceutical companies seek innovative partners to overcome formulation challenges, Arecor’s expertise—and its base in Cambridge—remain a valuable draw.
The agreement could lead to expanded collaboration and commercial opportunities for the firm, reinforcing its role as a key player in the future of pharmaceutical development.
